This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Ohlhausen backs FTC view that no-‘authorized generics’ deals can be anticompetitive

By Jeff Bliss and Leah Nylen ( April 29, 2014, 22:13 GMT | Insight) -- Republican US Federal Trade Commissioner Maureen Ohlhausen said Tuesday she backed the agency view that a branded drugmaker’s agreement to not offer an 'authorized generic' product to compete with a rival generic can hurt competition. Courts have debated the validity of that view in their attempt to determine what the US Supreme Court meant in June when it sided with the FTC in the Actavis case and said “large, unjustified payments” may violate antitrust law.Republican US Federal Trade Commissioner Maureen Ohlhausen said Tuesday she backed the agency view that a branded drugmaker’s agreement to not offer an 'authorized generic' product to compete with a rival generic can hurt competition....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections